BrainStorm announced that it received a notification letter from Nasdaq indicating that the company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCLI:
- BrainStorm announces agreement with FDA on SPA for Phase 3b ALS trial
- BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
- Biotech Alert: Searches spiking for these stocks today
- BrainStorm unveils NurOwn trial design at MDA Clinical and Scientific Conference
- BrainStorm submits SPA request to FDA for study of NurOwn
